
ONL Therapeutics completes enrollment in Phase 2 GALAXY trial for geographic atrophy
A first-in-class small-molecule Fas inhibitor delivered by intravitreal injection is now under evaluation in more than 324 patients across North America and Europe.
ONL Therapeutics has completed enrollment in GALAXY (NCT06659445), its global phase 2 clinical trial evaluating xelafaslatide in patients with
"Enrolling a large global trial with this many participants tells us that physicians and patients want a new approach to GA that significantly reduces treatment burden," said David N. Zacks, MD, PhD, chief scientific officer at ONL Therapeutics. "GA is a relentless, irreversible disease with few approved treatments, particularly in Europe. With the potential for dosing every three to six months, xelafaslatide brings a unique and differentiated mechanism of action designed to protect key retinal cells from Fas-mediated cell death to preserve vision."
Trial design
GALAXY is a multicenter, randomized, double-masked, sham-controlled phase 2 study enrolling patients at sites in the United States, Canada, and Europe.1 The trial randomizes participants across three experimental arms, testing two dose levels of xelafaslatide delivered at two treatment frequencies—every 12 weeks or every 24 weeks—alongside a sham control arm. A US-only active reference arm is also incorporated into the design.
The primary end point is the rate of GA lesion area growth versus sham at 48 weeks, assessed by fundus autofluorescence. Additional timepoints extend to 72 weeks. Topline data on the primary endpoint are anticipated in Q4 2027.1
Mechanism and drug background
Xelafaslatide (formerly ONL1204) is an investigational first-in-class small-molecule Fas inhibitor designed to protect key retinal cells, including photoreceptors, from cell death.1 According to ONL Therapeutics, death of these retinal cells, through both direct and inflammatory signaling pathways, is the root cause of vision loss and the leading cause of blindness.1
According to ONL Therapeutics, xelafaslatide has the potential for dosing every three to six months, which the company describes as a differentiator in reducing treatment burden.1
Prior clinical data
The GALAXY trial builds on data from a phase 1b study (NCT04744662) that demonstrated xelafaslatide to be generally safe and well tolerated, with encouraging efficacy signals observed after six months.1 ONL Therapeutics is also developing xelafaslatide in macula-off retinal detachment, where a US phase 2 study (NCT05730218) has been completed and the FDA has granted orphan drug designation, as well as in progressing open-angle glaucoma, where a phase 1b study (NCT05160805) has been completed.1
Clinical context
GA affects an estimated 5 million people worldwide and is characterized by progressive, irreversible loss of photoreceptors and RPE cells in the macula, leading to central vision loss.2 Until recently, no approved therapies existed for the condition; two complement inhibitors—pegcetacoplan and avacincaptad pegol—have since received FDA approval in the United States, though neither is currently approved in Europe.2
As an enrollment completion announcement, no efficacy or safety data from GALAXY are yet available. The 48-week primary endpoint readout is not expected until Q4 2027, with additional timepoints extending to 72 weeks.1
References
1. ONL Therapeutics completes enrollment in global Phase 2 GALAXY trial of xelafaslatide in patients with geographic atrophy associated with dry AMD. News release. PR Newswire. November 17, 2026. Accessed November 20, 2026. https://www.prnewswire.com/news-releases/onl-therapeutics-completes-enrollment-in-global-phase-2-galaxy-trial-of-xelafaslatide-in-patients-with-geographic-atrophy-associated-with-dry-amd-302941393.html
2. Fleckenstein M, Keenan TDL, Guymer RH, et al. Age-related macular degeneration. Nat Rev Dis Primers. 2021;7(1):31. Published 2021 May 6. doi:10.1038/s41572-021-00265-2
Related to this article








